Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$832.00K$832.00K— vs Q1 2021 Net Income-$94.77M-$94.77MN/M vs Q1 2021 EPS Diluted-$1.74-$1.74N/M vs Q1 2021 Operating Income-$101,145,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$100,539,000N/M Margins · derivedOperating margin-12156.9%
Net margin-11391.1%
ended Mar 31, 2022 · filed May 5, 2022 · 35 d after period end